Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Camrelizumab + apatinib + chemotherapy as neoadjuvant therapy for resectable stage II-III esophageal squamous cell carcinoma
ChiCTR2100051763Phase 4Not yet recruiting
- Sponsor
- The First Affiliated Hospital of Sun Yat-sen University
- Start
- Oct 2021
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of camrelizumab, Rivoceranib, paclitaxel and carboplatin in Esophageal Squamous Cell Carcinoma (ESCC), sponsored by The First Affiliated Hospital of Sun Yat-sen University. Primary endpoint: Pathological complete response rate. Planned start Oct 2021; status: not yet recruiting.
02
Drugs
camrelizumabRivoceranibpaclitaxelcarboplatin
03
Conditions
Esophageal Squamous Cell Carcinoma (ESCC)
Beyond the preview
Go deeper on ChiCTR2100051763.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100051763.